We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

95 hedge funds and large institutions have $423M invested in Apellis Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 11

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

32% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 25

20% more funds holding

Funds holding: 79 → 95 (+16)

4.2% more ownership

Funds ownership: 52.88% → 57.09% (+4.2%)

20% less capital invested

Capital invested by funds: $528M → $423M (-$105M)

Holders
95
Holders Change
+16
Holders Change %
+20.25%
% of All Funds
2.12%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
27
Increased
33
Reduced
25
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VP
venBio Partners
California
+$27.5M
2
BlackRock
BlackRock
New York
+$13.5M
3
FT
Fiduciary Trust
Massachusetts
+$10.8M
4
CAM
Cormorant Asset Management
Massachusetts
+$5.06M
5
O
OrbiMed
New York
+$5.02M

Top Sellers

Rank Fund Capital Flow
1
HIM
Hillhouse Investment Management
Cayman Islands
-$34.2M
2
RCM
RA Capital Management
Massachusetts
-$16M
3
SI
Sofinnova Investments
California
-$7.67M
4
VC
Vivo Capital
California
-$7.36M
5
State Street
State Street
Massachusetts
-$4.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$2.96M +$600K +39,130 +21%
BBA
27
Baker Bros. Advisors
New York
$2.59M – – –
Charles Schwab
28
Charles Schwab
California
$2.54M -$1.84K -120 -0.1%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.02M +$152K +9,932 +7%
AA
30
ALPS Advisors
Colorado
$1.71M +$469K +30,560 +31%
SFM
31
Sphera Funds Management
Israel
$1.54M -$1.46M -95,470 -45%
Point72 Asset Management
32
Point72 Asset Management
Connecticut
$1.46M +$1.7M +111,016 New
EP
33
Eversept Partners
New York
$1.41M +$101K +6,585 +7%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$1.02M +$430K +28,033 +57%
TA
35
Teachers Advisors
New York
$959K – – –
TCIM
36
TIAA CREF Investment Management
New York
$925K -$31.5K -2,054 -3%
UBS Group
37
UBS Group
Switzerland
$847K +$585K +38,146 +147%
Swiss National Bank
38
Swiss National Bank
Switzerland
$836K – – –
Goldman Sachs
39
Goldman Sachs
New York
$767K -$228K -14,892 -20%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$758K -$45K -2,936 -5%
Morgan Stanley
41
Morgan Stanley
New York
$747K -$56K -3,647 -6%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$747K +$21.1K +1,377 +2%
Citigroup
43
Citigroup
New York
$672K +$52K +3,386 +7%
Citadel Advisors
44
Citadel Advisors
Florida
$663K -$206K -13,443 -21%
SI
45
Sofinnova Investments
California
$654K -$7.67M -500,000 -91%
AllianceBernstein
46
AllianceBernstein
Tennessee
$633K – – –
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$620K +$234K +15,225 +48%
Squarepoint
48
Squarepoint
New York
$566K +$335K +21,804 +103%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$490K -$23K -1,500 -4%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$489K +$4.6K +300 +0.8%
1
2
3 4 5

APLS Hedge Fund Activity: Q4 2018 in Review

95 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2018, worth a combined $423M — down 20% from $528M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new APLS positions and 11 closed out — a net gain of 16 holders — while 33 added to existing stakes and 25 trimmed.

The largest buyer was venBio Partners, opening a new position worth an estimated $27.5M. The largest seller was Hillhouse Investment Management, cutting an estimated $34.2M.

  • 95 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2018, up from 79 in Q3 2018.
  • Funds reported $423M of Apellis Pharmaceuticals stock for Q4 2018, down 20% quarter-over-quarter.
  • 27 funds opened new Apellis Pharmaceuticals positions in Q4 2018 and 11 closed out, a net change of +16 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2018 was venBio Partners, an estimated $27.5M added.
  • The largest Apellis Pharmaceuticals seller in Q4 2018 was Hillhouse Investment Management, an estimated $34.2M sold.

Based on aggregated 13F filings for Q4 2018.